Research programme: monoclonal antibody therapeutics - arGEN-X/Bird Rock Bio

Drug Profile

Research programme: monoclonal antibody therapeutics - arGEN-X/Bird Rock Bio

Alternative Names: Anti-interleukin 22 monoclonal antibody; Anti-Nav1.7 monoclonal antibody; ARGX-112; Monoclonal antibodies targeting GPCR receptors - Bird Rock Bio

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator arGEN-X
  • Developer arGEN-X; Bird Rock Bio
  • Class Monoclonal antibodies
  • Mechanism of Action G protein-coupled receptor modulators; Interleukin 22 receptor antagonists; Interleukin 6 inhibitors; Nav1.7-voltage-gated-sodium-channel-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Inflammation; Ovarian cancer; Pain; Renal cancer; Skin disorders

Most Recent Events

  • 21 May 2015 arGEN-X and LEO Pharma agree to collaborate on monoclonal antibody therapeutics, including ARGX 112, for inflammatory Skin disorders
  • 18 Feb 2015 arGEN-X in-licenses GS Xceed™ System technology from Lonza )
  • 27 Mar 2014 RuiYi secures loan ($US15 million in Series B financing) from existing investors to finance development of RYI 008 and the discovery and development of therapeutic mAbs targeting GPCR receptors (including RYI 018) for Autoimmune diseases and Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top